This Anti-Fibrotic Drug Development conference will be a unique opportunity for drug developers focused on organ-specific indications to participate in a cross-disciplinary, multi-organ discussions in order to gain new insights into their anti-fibrotic drug development research. Attending this comprehensive forum will enable you to; identify which fibrotic mechanisms are driving pathology changes in humans; effectively translate from preclinical to clinical development and robustly select patient populations.